I returned to the hospital.
Putting what had happened in New York behind me, I found Palo Alto at Stanford far more peaceful—and the weather much better—than bustling New York.
Compared with a sprawling city that was so hard to get around.
As always, the wards at Stanford were bustling. First, I had to catch up on the patients.
I dropped into a seat at the nurses' station.
A lot had changed among the patients during the few days I was in New York. Some had gotten worse, while a few had improved.
The patient with pseudomembranous colitis I'd been seeing had been discharged, fully recovered... That's good.
This man had multiple myeloma and had developed tiny fractures in his legs. That man's heart had worsened, so he had started taking warfarin.
I quickly skimmed the medical records to see whether any prescriptions needed changing or anything needed further thought.
Was there a new disease, or a diagnosis whose treatment was still unknown in the 1970s?
Nothing immediately caught my eye.
I sat there, continuing to flip through the medical records for the internal medicine ward. Alice passed by with a stethoscope and raised a hand to greet me.
“Oh, you're back. Did you go to the awards ceremony?”
“Yeah.”
“Let's go get lunch later.”
Alice stopped talking and hurried off somewhere, checking a wristwatch as she went.
About an hour passed.
Just as I was finishing the medical records for my ward, I turned at the feeling of someone staring at the back of my head. Someone was watching me from behind.
That startled me.
“You're the resident, right?”
I turned around. He probably meant me.
“Good afternoon, Professor.”
This was Professor Henry Kaplan of Stanford's hematology-oncology department. He was quite famous.
He was a doctor who studied non-Hodgkin lymphoma and established a treatment for it. Even in the 1970s, he was already fairly well known in medical circles.
He looked at me.
“You're the resident who just won the Lasker Award, right? I have a few patients with unexplained neurological symptoms. Could you take a look at them?”
“Yes, of course.”
Professor Kaplan let out a sigh of relief.
As if he'd finally reached a safe harbor.
“The dean told me you can figure out what's causing an illness just by looking at a patient.”
“That's too kind.”
“You don't need to be so modest. I heard you identified a Kawasaki disease patient that the entire pediatrics department had missed, and even figured out how to treat it.”
That was all true. Though Kawasaki disease had already been studied by then.
Professor Kaplan looked at me again with a grave expression, as if remembering a tragedy.
“That's right.”
“Let's see if you can help my patient, too. He's the father of three daughters. We need to get him home in one piece, no matter what, don't we?”
Doctors don't make promises they can't guarantee. That goes for other doctors, too.
“I'll do my best.”
“Don't feel pressured.”
How could I not feel pressured?
The cost of failure was too high. And there was no reason to believe a clean victory was possible.
***
Still, it was an interesting puzzle.
Neurological symptoms developing after cancer were quite common. There were plenty of possible causes, too.
There was a lot to consider.
The most common cause was side effects from anticancer drugs.
Cancer cells are human cells with human genes. It wasn't easy to kill only cancer cells while leaving healthy cells alive.
Platinum-based chemotherapy drugs, such as cisplatin, were notorious for causing neuropathy. That could be the cause, too.
I'd know once I examined the patient.
Whether the neurological symptoms were caused by medication, by cancer metastasizing to the brain, or by something else entirely.
Professor Kaplan strode toward the oncology ward, and I followed. He seemed to be in a hurry.
“What kind of cancer does he have?”
“Lung cancer.”
“What kind of lung cancer?”
“The cells are small.”
Small-cell lung cancer, then. That added another diagnosis to consider. Small-cell lung cancer was a strange kind of cancer.
‘This is getting complicated.’
To explain.
Small-cell lung cancer is a neuroendocrine tumor.
That means it can produce hormones and neurotransmitters. That added a few more possible diagnoses...
This was getting troublesome.
“How have the symptoms progressed?”
“We did a biopsy, then treated him with chemotherapy and radiation. The cancer is shrinking as planned, but since yesterday, he hasn't been able to speak. Like a stroke.”
“It isn't a stroke, is it?”
You always had to rule out the simplest explanation first. Professor Kaplan nodded.
Let's think it over for now.
***
I entered the patient's room.
“Hello, sir.”
Just as Professor Kaplan had said, the patient was an ordinary middle-aged man. Three children were gathered around his bed. It seemed he'd brought his whole family to visit after hearing that his condition had worsened.
It was a grim sight, just imagining what would happen if the treatment failed.
A woman about the same age as the patient, presumably his wife, hurried forward.
“Have you figured out what's wrong? He'll get better, right? It's already been two days...”
“I'll take a look.”
“He can't even speak. He just lies there.”
I turned toward the patient, who made a strained gesture at me. It seemed like he was trying to communicate something...
Aphasia?
I leaned closer to the patient.
“Can you understand what I'm saying?”
“Yes...”
“Where does it hurt? What are you feeling?”
“I can't get any strength in my legs...”
Fortunately, this wasn't true aphasia. He wasn't completely unable to speak; there seemed to be some impairment in his ability to function.
It looked like his brain function had declined diffusely, slowing his thoughts, or perhaps his vocal cords had grown weak.
It didn't seem to be a focal lesion in the language-control area, as in stroke-induced aphasia.
Both his fluency and comprehension were intact.
I took a reflex hammer from my pocket, steadied his knee, and tapped the tendon. Let's see if his knee reflexes were intact.
The knee-jerk reflex was suppressed.
That was a sign of a lower motor neuron lesion.
This time, I ran the handle of the hammer along the sole of his foot, and his toes immediately extended upward like a bow. A Babinski sign.
An upper motor neuron lesion.
That meant there was a problem at the level of the brain and spinal cord.
That was unusual.
There were signs of both lower and upper motor neuron lesions. Still, I was beginning to get an idea.
I turned back to the patient.
“Then I'll see you again this evening.”
The patient gave a strained nod, while his three children stared at me intently.
***
We returned to the nurses' station in the oncology ward.
I'd narrowed down the possibilities quite a bit.
I was close enough to come up with a diagnosis. I looked at Professor Kaplan.
“He's receiving mannitol right now, isn't he?”
Professor Kaplan nodded.
“Can you see that just by looking at me?”
With diffuse impairment of brain function and no focal brain lesion, cerebral edema was the first thing to suspect. And he'd said it wasn't a stroke.
“No, well... As you can see, Professor, this patient has signs involving both upper and lower motor neurons. We can rule out a structural problem like a stroke, as well as chemotherapy side effects.”
The professor furrowed his brow.
“Why chemotherapy side effects?”
“Chemotherapy drugs generally don't cross the blood-brain barrier. Neuropathy caused by chemotherapy is usually limited to the peripheral nerves.”
“Is that so? Well, that's what the theory says.”
Professor Kaplan had established the methods of chemotherapy and radiation therapy for cancers like this.
But how chemotherapy drugs worked in practice, and what side effects they caused, must still have been a mystery even to the people who developed them.
In any case, it wasn't the chemotherapy.
The answer was clear.
Autoimmune encephalitis.
It could cause all sorts of symptoms, including neuropsychiatric symptoms and seizures.
Just like in this patient's case.
Muscle weakness, personality changes, depression, anxiety, confusion, seizures, ataxia, pain, and more. The reason it caused depression and anxiety was a fascinating subject, too, but that was for later.
“Did the patient have a seizure yesterday?”
Hadn't the whole family rushed to the hospital because he'd started having a seizure the day before?
Thinking he was going to die.
“He did.”
Come to think of it, perhaps the relevant neural receptor hadn't been discovered yet. I paused to consider how best to explain it.
“It's autoimmune encephalitis. It causes diffuse brain damage, as well as damage to both the upper and lower motor neurons.”
“What's that?”
“An autoimmune disease... like lupus.”
“Lupus encephalitis?”
“It means there are autoantibodies.”
Professor Kaplan furrowed his brow slightly.
As expected, that was the look of someone who didn't believe me. His eyes seemed to ask what kind of nonsense I was talking about.
And that was fair, wasn't it?
In the 1970s, the concept of autoimmune encephalitis didn't yet exist. More than that, the very principles of autoimmunity weren't well understood.
“So this patient has a disease no one's heard of, with a mechanism that's unclear.”
“Uh, yes.”
“That's a complicated hypothesis. Could you explain it in more detail?”
I thought about how to answer.
It was a valid point, but in this case, it was helpful. That complicated hypothesis led to a conclusion—and a possible treatment.
Namely...